We would like to take this opportunity to express our sincere appreciation to those who have supported the Institute of Health Sciences (IHS) over the last ten years. Your tireless contributions, from helping to establish our mission to accomplishing every milestone along the way, have made this institution possible. We want to express a sincere thank you!
IHS began its operation in 2002 as a joint venture of the Shanghai Institutes for Biological Sciences of the Chinese Academy of Sciences (CAS) and the Shanghai Jiao Tong University School of Medicine. This joint effort takes advantage of the extensive basic biological research of CAS, and the excellent medical education, healthcare, and clinical research of Jiao Tong University School of Medicine. IHS is the nation's first and foremost non-profit research organization devoted to translational medicine, with a specific goal of bridging basic biomedical research and health issues.
Building upon their excellent foundation in basic biomedical research and clinical expertise, IHS scientists strive to discover novel therapeutic strategies for many diseases, including cancer, autoimmune disorders, cardiovascular, and neurodegenerative diseases. To achieve this goal, the Institute has organized 27 research groups, each led by an expert recruited world-wide. Our main emphasis is the elucidation of disease mechanisms, from which we can develop new approaches for disease prevention and treatment. Our multi-pronged approach involves research in three major areas of translational medicine: (1) stem cell biology and its clinical application; (2) immune regulation and autoimmunity; and (3) cancer biology, prevention and therapy. We have also established ten state-of-the-art technology platforms, which include specialized core facilities for: stem cell development, gene profiling , imaging, flow cytometry, GMP for cell culture, proteomics, experimental animals, and a human tumor bank. With this combination of expertise and technology, we are confident that IHS is well-positioned to achieve its mission of excellence in translational biomedical research and education in the coming years.
Over the past 10 years, we have made significant progress in both basic and translational medical research. Our research budget has increased steadily, and many of our findings have been published in highly-regarded peer-reviewed journals, including Nature Medicine, Nature Immunology, Cell Stem Cell, Journal of Clinical Investigation, PNAS, and Blood. We have made excellent progress in stem cell-based therapy, microRNA-based diagnosis, disease-specific gene identification, and novel therapeutic target discovery.
Owing to the booming economic development in China, significant changes in life style and living environment are occurring, and these changes have brought with them new health challenges. With government-led emphasis on improving the general health of the population, we anticipate that the diverse research enterprise at IHS can meet these new health challenges by strengthening innovation, accelerating translational research, and training new scientists in translational medicine.
It is through your efforts that the growth of IHS has been nurtured during its first ten years. With your continued support, we are confident that the next ten years will be even more prosperous.